Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Wardelmann

Showing results (241-250 of 248) with videos related to

Pageof 25
Sort By:
You have reached the last page of results.This site can display upto 248 results.
Cancers|June 11, 2020
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation StudyChristoph Schliemann, Mirjam Gerwing, Hauke Heinzow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2024
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor EscapeThomas Mühlenberg, Johanna Falkenhorst, Tom Schulz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2017
Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group InitiativeTine Cuppens, Daniela Annibali, An Coosemans, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2022
Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue SarcomaSylvie Bonvalot, Piotr L Rutkowski, Juliette Thariat, et al.
The Lancet. Oncology|July 13, 2019
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trialSylvie Bonvalot, Piotr L Rutkowski, Juliette Thariat, et al.
Cancer Research|June 8, 2026
Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide ImagesArianna Bonetti, Van-Linh Le, Zunamys I Carrero, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2025
Advancing sarcoma diagnostics with expanded DNA methylation-based classificationNatalie Jäger, David E Reuss, Martin Sill, et al.
Nature Communications|January 22, 2021
Sarcoma classification by DNA methylation profilingChristian Koelsche, Daniel Schrimpf, Damian Stichel, et al.
Pageof 25

Showing results (241-250 of 248) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 248 results.
Cancers|June 11, 2020
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation StudyChristoph Schliemann, Mirjam Gerwing, Hauke Heinzow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2024
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor EscapeThomas Mühlenberg, Johanna Falkenhorst, Tom Schulz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2017
Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group InitiativeTine Cuppens, Daniela Annibali, An Coosemans, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2022
Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue SarcomaSylvie Bonvalot, Piotr L Rutkowski, Juliette Thariat, et al.
The Lancet. Oncology|July 13, 2019
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trialSylvie Bonvalot, Piotr L Rutkowski, Juliette Thariat, et al.
Cancer Research|June 8, 2026
Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide ImagesArianna Bonetti, Van-Linh Le, Zunamys I Carrero, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2025
Advancing sarcoma diagnostics with expanded DNA methylation-based classificationNatalie Jäger, David E Reuss, Martin Sill, et al.
Nature Communications|January 22, 2021
Sarcoma classification by DNA methylation profilingChristian Koelsche, Daniel Schrimpf, Damian Stichel, et al.
Pageof 25